Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16045620 | 0.88 | MAPT (0.36) | MAPTTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL17266586 | 0.86 | MAPT (0.39) | MAPTTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL10456507 | 0.83 | MAPT (0.38) | MAPTTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL9794654 | 0.80 | MAPT (0.36) | MAPT | |
| SCHEMBL3897341 | 0.78 | MAPT (0.35) | MAPTTSHR | |
| SCHEMBL11507622 | 0.78 | MAPT (0.36) | MAPTTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL1093310 | 0.77 | MAPT (0.37) | MAPTTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL16045305 | 0.77 | MAPT (0.34) | MAPT | |
| Methacrylic Acid SCHEMBL7860381 | 0.77 | TSHR (0.44) | MAPTTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL304713 | 0.77 | MAPT (0.34) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114539169-A | Method for synthesizing pyrazine ring containing substituent | 江苏恒盛药业有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-105367498-A | Pyrazolo-cyclo-3-carboxamide analog and its preparation method and use | UNIV CHINA AGRICULTURAL | 2016-03-02 | — | — | CN | claimed |
| CN-102731335-B | A kind of post-treating method of oxalate hydrogenation liquid | JIANGSU DANHUA COAL CHEMICAL PRODUCT ENGINEERING TECHNOLOGY CO., LTD. (CN) | 2015-12-09 | — | — | CN | claimed |
| CN-104844448-A | Synthetic method of Dl - salvianic acid | XIAMEN SHENGJIANDA BIOTECH CO LTD | 2015-08-19 | — | — | CN | claimed |
| CN-101830776-B | Method for synthesizing ethanol | UNIV ZHEJIANG | 2013-09-25 | — | — | CN | claimed |
| CN-101823993-A | Preparation method of L-octohydroindoline-2-formic acid | ANHUI SHIHUA CHEMICAL CO LTD | 2010-09-08 | — | — | CN | claimed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-08-30 | — | — | US | disclosed |
| CN-114539169-A | Method for synthesizing pyrazine ring containing substituent | 江苏恒盛药业有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-6596772-B1 | Relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are | SUGEN, INC. | 2003-07-22 | — | — | US | disclosed |
| CN-1088084-C | Cyanacrylate adhesive | HENKEL KGAA (DE) | 2002-07-24 | — | — | CN | disclosed |
| EP-1212296-A1 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016097-A1 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| CN-1219949-A | Cyanacrylate adhesive | HENKEL KGAA (DE) | 1999-06-16 | — | — | CN | disclosed |
| US-4958026-A | HYPOTENSIVE AGENTS | SCHERING AKTIENGESLLSCHAFT (DE) | 1990-09-18 | — | — | US | disclosed |
| US-4476132-A | Acylquinolinone derivatives, and antiallergic preparations and methods of inhibiting allergic reactions using them | CIBA-GEIGY CORPORATION (US) | 1984-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | MAPT 4883/4885TSHR 1187/4885CHRM2 220/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | MAPT 4883/4885TSHR 1187/4885CHRM2 220/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | MAPT 4883/4885TSHR 1187/4885CHRM2 220/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | MAPT 4883/4885TSHR 1187/4885CHRM2 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.